Industry Segment Information (Tables)

9 Months Ended

Sep. 29, 2024

Segment Reporting [Abstract]

Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations

Revenue and operating income (loss) from continuing operations by reportable segment are shown in the table below:  

	Three Months Ended				Nine Months Ended
	September 29, 2024		October 1, 2023		September 29, 2024		October 1, 2023
	(In thousands)
Segment Revenues
Life Sciences	$	300,921	$	307,855	$	917,805	$	972,649
Diagnostics	383,333		363,090		1,108,470		1,082,639
Revenue purchase accounting adjustments	(205)		(206)		(621)		(618)
Total revenues	$	684,049	$	670,739	$	2,025,654	$	2,054,670
Segment Operating Income
Life Sciences	$	102,979	$	114,192	$	317,105	$	371,410
Diagnostics	101,434		81,741		274,779		241,414
Corporate	(10,915)		(11,323)		(33,725)		(34,727)
Subtotal reportable segments adjusted operating income	193,498		184,610		558,159		578,097
Amortization of intangible assets	(89,642)		(90,920)		(271,500)		(275,489)
Purchase accounting adjustments	(103)		(1,080)		(7,348)		(3,057)
Acquisition, divestiture and rebranding costs	(4,874)		(12,550)		(22,115)		(59,080)
Significant litigation matters and settlements	(810)		—		(7,086)		—
Significant environmental matters	—		—		—		(1,132)
Restructuring and other, net	82		(10,832)		(22,119)		(15,936)
Operating income from continuing operations	98,151		69,228		227,991		223,403
Interest and other (income) expense, net (see Note 4)	(2,206)		18,625		6,423		71,806
Income from continuing operations before income taxes	$	100,357	$	50,603	$	221,568	$	151,597